The US Food and Drug Administration issued a notice on the 9th stating that the use of glucagon-like peptide-1 receptor agonists may increase the risk of “non-arteritic anterior ischemic optic neuropathy”. The disease may cause an acute loss of painless vision in one eye, permanent vision loss in severe cases, and requires all relevant drug marketing application holders to add risk warnings to drug instructions. The drugs involved include simeglutide, liraglutide, and tirpotide. A summary analysis of 126 randomized controlled clinical trials showed that the incidence of NAION in patients using such drugs was 6.4 cases per 100,000 people per year, and 3.8 cases per 100,000 people per year in the control group.

The US Food and Drug Administration issued a notice on the 9th stating that the use of glucagon-like peptide-1 receptor agonists may increase the risk of “non-arteritic anterior ischemic optic neuropathy”. The disease may cause an acute loss of painless vision in one eye, permanent vision loss in severe cases, and requires all relevant drug marketing application holders to add risk warnings to drug instructions. The drugs involved include simeglutide, liraglutide, and tirpotide. A summary analysis of 126 randomized controlled clinical trials showed that the incidence of NAION in patients using such drugs was 6.4 cases per 100,000 people per year, and 3.8 cases per 100,000 people per year in the control group.